We serve Chemical Name:4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid CAS:191018-57-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid
CAS.NO:191018-57-2
Synonyms:4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid
Molecular Formula:C11H10F2O3
Molecular Weight:228.19200
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:382.7ºC at 760mmHg
Density:1.312g/cm3
Index of Refraction:1.506
PSA:54.37000
Exact Mass:228.06000
LogP:2.25830
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid Use and application,4-(3,4-difluorophenyl)-2-methyl-4-oxobutanoic acid technical grade,usp/ep/jp grade.
Related News: Injectable drug devices such as pens and cartridges accounted for 45% of the company’s sales last year, followed by insulin products with 16%. poly(melamine-co-formaldehyde), butylated manufacturers Since it emerged as a shareholder of GSK in April, Elliott has reportedly been trying to gin up investor support to move Walmsley to the consumer health spinoff rather than to let her lead the new GSK after the separation. α-Lipoic Acid suppliers Injectable drug devices such as pens and cartridges accounted for 45% of the company’s sales last year, followed by insulin products with 16%. Neohesperidin vendor & factory In his new role, Grégoire will ensure alignment between NOVA’s business strategy, operations and growth objectives, as well as leading the Modelling and Simulation (M&S) team as NOVA embarks on its next phase of expansion.,The company’s contract arm churns out more than 250 metric tons of commercial APIs every year for injectables, inhalables, highly potent, cytotoxic and controlled substances, according to a release.
